|Portfolio||Paediatric, foetal and maternal health|
Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative. The EcLiPSE study aimed to find out whether children and young people with long lasting seizures should be treated with phenytoin or levetiracetam in an emergency setting.
EcLiPSE was undertaken at 30 UK emergency departments in secondary and tertiary care centres. 286 participants aged 6 months to under 18 years were randomised and treated and had available data.
Although levetiracetam was not significantly superior to phenytoin, the results, together with previously reported safety profiles and comparative ease of administration of levetiracetam, suggest it could be an appropriate alternative to phenytoin as the first-choice, second-line anticonvulsant in the treatment of paediatric convulsive status epilepticus
- Lyttle, MD., et al. (2019). Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial
- Woolfall, K., Young, B., Frith, L., Appleton, R., Iyer, A., Messahel, S, Hickey, H, Gamble, C. (2014). Doing challenging research studies in a patient-centred way: A qualitative study to inform a randomised controlled trial in the paediatric emergency care setting. BMJ Open, 4(5)